# The ctDNA-RECIST Trial Part One

> **NCT06562348** · PHASE2 · RECRUITING · sponsor: **Karen-Lise Garm Spindler** · enrollment: 167 (estimated)

## Conditions studied

- Gastrointestinal Neoplasm

## Interventions

- **OTHER:** Standard of care
- **OTHER:** ctDNA-RECIST guided palliative systemic treatment

## Key facts

- **NCT ID:** NCT06562348
- **Lead sponsor:** Karen-Lise Garm Spindler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2029-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562348, "The ctDNA-RECIST Trial Part One". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06562348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*